About Celmatix
Celmatix is a company based in New York (United States) founded in 2009.. Celmatix has raised $24.89 million across 7 funding rounds from investors including Regional Economic Development Councils and Topspin Consumer Partners. The company has 27 employees as of December 31, 2022. Celmatix offers products and services including AMHR2 Agonist Program, Oral FSH Receptor Agonist, and JNK Inhibitor. Celmatix operates in a competitive market with competitors including Invitae, Myriad Genetics, Genome Medical, Centogene and Fulgent Genetics, among others.
- Headquarter New York, United States
- Employees 27 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Celmatix Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$24.89 M (USD)
in 7 rounds
-
Latest Funding Round
$4.5 M (USD), Series C
Dec 18, 2017
- Investors
-
Employee Count
27
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Celmatix
Celmatix offers a comprehensive portfolio of products and services, including AMHR2 Agonist Program, Oral FSH Receptor Agonist, and JNK Inhibitor. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets ovarian aging and related health issues in women.
Advances infertility therapies through targeted hormone stimulation.
Addresses inflammation and pain in women's health conditions.
Unlock access to complete
Unlock access to complete
Funding Insights of Celmatix
Celmatix has successfully raised a total of $24.89M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $4.5 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series C — $4.5M
-
First Round
First Round
(16 Feb 2011)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2017 | Amount | Series C - Celmatix | Valuation |
investors |
|
| Mar, 2016 | Amount | Series C - Celmatix | Valuation |
investors |
|
| Aug, 2015 | Amount | Series C - Celmatix | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Celmatix
Celmatix has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Regional Economic Development Councils and Topspin Consumer Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Topspin Consumer Partners is engaged in private equity investments focused on consumer brands.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Celmatix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Celmatix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Celmatix Comparisons
Competitors of Celmatix
Celmatix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Invitae, Myriad Genetics, Genome Medical, Centogene and Fulgent Genetics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Home-based genetic tests for detecting diseases are provided to individuals.
|
|
| domain | founded_year | HQ Location |
Molecular diagnostics and personalized medicine for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Genomic testing services are provided clinically and directly to consumers.
|
|
| domain | founded_year | HQ Location |
Provider of biochemical/genetic tests to detect mutations and rare diseases
|
|
| domain | founded_year | HQ Location |
Provider of genetic testing services for carrier screening cardiovascular diseases, epilepsy and cancer
|
|
| domain | founded_year | HQ Location |
High-throughput gene sequencing platform is developed for clinical diagnostics.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Celmatix
Frequently Asked Questions about Celmatix
When was Celmatix founded?
Celmatix was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Where is Celmatix located?
Celmatix is headquartered in New York, United States. It is registered at New York, New York, United States.
Is Celmatix a funded company?
Celmatix is a funded company, having raised a total of $24.89M across 7 funding rounds to date. The company's 1st funding round was a Series C of $3.76M, raised on Feb 16, 2011.
How many employees does Celmatix have?
As of Dec 31, 2022, the latest employee count at Celmatix is 27.
What does Celmatix do?
Celmatix focuses on womens health. It uses predictive analytics and genomics to create products that help in infertility treatment and proactive fertility management. The company offers POLARIS, a cloud- based analytics platform for optimizing a womans fertility by calculating the personal likelihood of success using various fertility treatment options, tailored to a patients clinical metrics. In addition, the company offers Fertilome, an NGS assay that enables women to evaluate present and future fertility potential. Fertilome analyzes 49 different variants in 32 genes, and is specifically aimed at women who plan to freeze their eggs, have children after the age of 35, or have risk factors that affect fertility such as PCOS, depleted ovarian reserve, endometriosis or other endocrine disorders.
Who are the top competitors of Celmatix?
Celmatix's top competitors include Fulgent Genetics, Centogene and Myriad Genetics.
What products or services does Celmatix offer?
Celmatix offers AMHR2 Agonist Program, Oral FSH Receptor Agonist, and JNK Inhibitor.
Who are Celmatix's investors?
Celmatix has 2 investors. Key investors include Regional Economic Development Councils, and Topspin Consumer Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.